Immunic Inc.

10/28/2021 | Press release | Distributed by Public on 10/28/2021 04:33

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis